The company
NiSCELL is short for Nichi Asia Life Science, a cell therapy company in Petaling Jaya, Selangor. It manufactures immune cell and stem cell products in its own cleanrooms, it runs research with three Malaysian universities, and it has been doing both for fifteen years.
Every cell therapy company says it is a global leader at the forefront of the field. NiSCELL is not going to say that. The category has enough of it, and none of it can be checked. Here is what can be checked instead: the facility is cGMP accredited by the NPRA, the company holds BioNexus status, the platform was transferred from the Biotherapy Institute of Japan in 2009, and the umbilical cord tissue is collected to the standards of the American Association of Tissue Banks, 15th edition. Every product on this site is published with a line saying what it is not.
NiSCELL is short for Nichi Asia Life Science. Nichi is the Japanese element in the name, and it is not decoration. In 2009 the company's cell therapy technology was transferred from the Biotherapy Institute of Japan. That transfer is where the immunotherapy platform comes from, and the company has been running it ever since.
Cell therapy technology transferred from the Biotherapy Institute of Japan. This is the immunotherapy platform the company still runs, and the reason the company is called Nichi Asia.
Research begins on allogeneic mesenchymal stem cells (MSC), meaning cells prepared from a screened donor rather than from the recipient.
Research collaborations with Universiti Sains Malaysia (USM) and Universiti Teknologi MARA (UiTM) begin, running to 2017.
MSC, conditioned media and immunotherapy work runs in parallel. NK cell activity testing is established as an immune monitoring tool.
Research collaboration with Universiti Putra Malaysia (UPM) on exosomes begins, and continues today.
NiSCELL is a small company. The people listed here are the people who do the work, with the dates they started. Photographs are the company's own.
Chief Executive Officer
Dr Rajbans Singh started Malaysia's first geriatric ward, at Hospital Seremban, and was the first geriatrician in the country's Ministry of Health. He trained in the United Kingdom on a government scholarship and consults at Pantai Hospital Bangsar. He is President of the Malaysian Wellness Society. His career has focused on healthy ageing and preventing disease.
Company record
Chief Scientist and Production Head
Dr Sellamuthu has led NiSCELL's research and production since 2013. He trained in stem cell therapy at the University of Utah before completing a PhD in Regenerative Medicine at the University of Madras. He has developed culture protocols for several stem cell and immune cell types, and has published more than twenty research articles in the field.
Since 2013Company record
QA Assistant Manager and Regulatory Science Officer
Farah Dalila Mohd Zain has led NiSCELL's quality assurance since 2015. She coordinates internal audits and the external audits carried out by the NPRA and the Ministry of Health. She holds a BSc in chemistry and biology from Universiti Teknologi MARA (UiTM) and is certified in international GMP and quality management systems.
Since 2015Company record
QC Assistant and flow cytometry specialist
Ezzati Radzuan leads NiSCELL's quality control work and is the company's specialist in flow cytometry, the technique used to count and characterise cells. She analyses NK cells, T cells and mesenchymal stem cells from several tissue sources. She joined in 2014 and holds a BSc in molecular biology from Universiti Teknologi MARA (UiTM).
Since 2014Company record
Research and development
Susmita Kumarason works across NiSCELL's research and development, supporting cell isolation, expansion and analysis for the company's stem cell and immune cell products. She holds a first-class degree in biotechnology from Amrita University and a master's in advanced biological sciences from the University of Liverpool.
Company record
Scientific advisor, cell therapy
Dr Vignesh Sugumaran is a medical doctor with more than fourteen years of experience. He trained first in occupational medicine, in Ireland. His interest in healthy ageing led him into cell therapy, and in 2014 he was recognised as a professional member of international stem cell transplant and cell therapy associations.
Company record
Scientific advisor, immuno-oncology
Dr Rafeezul Mohamed is a senior lecturer at the Advanced Medical and Dental Institute of Universiti Sains Malaysia (USM), working in immuno-oncology and cardiovascular biology. He holds a PhD in cellular immunology from the University of Surrey. He has served as a research consultant to NiSCELL on immunotherapy studies.
Public record
Scientific advisor, haematology
Dr Faridah Idris is a haematologist and a scientific advisor to NiSCELL. She holds an MBBS and a Master of Pathology in haematology, both from Universiti Malaya, and a certificate in curriculum and instruction from Maastricht.
Company record
Each entry carries the same label as the claims register on the evidence page. Public record means the fact can be checked with a body other than NiSCELL. Company record means NiSCELL is the source. The label is published so a reader can weigh each line rather than take this page’s word for it. Advisors provide scientific input and are listed by their own qualifications. Their institutions are named to identify them, not as institutional endorsement of NiSCELL.